Dec 17, 2025 09:17AM
Dec 17, 2025 09:16AM
Oct 1, 2025 01:20PM
Oct 1, 2025 01:13PM
Mar 25, 2025 04:05PM
Mar 5, 2025 08:43AM
Mar 5, 2025 08:42AM Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Feb 5, 2025 06:30AM
Nov 4, 2024 07:30AM
Oct 24, 2024 06:29AM
Aug 13, 2024 04:05PM
Aug 12, 2024 08:07AM
Aug 12, 2024 08:00AM
Feb 7, 2024 08:01PM Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH
Nov 17, 2023 08:30AM
Nov 13, 2023 08:30AM
Nov 13, 2023 08:30AM
Jul 19, 2023 08:30AM
May 31, 2023 08:55AM
May 31, 2023 08:54AM
Apr 12, 2023 08:46AM Tenax Therapeutics (TENX) Provides 2023 Business Update
Apr 12, 2023 08:45AM
Mar 22, 2023 08:46AM
Mar 22, 2023 08:45AM
Feb 3, 2023 08:21AM
Feb 3, 2023 08:19AM
Feb 1, 2023 04:37PM
Feb 1, 2023 04:31PM Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
Sep 15, 2022 08:34AM
Sep 15, 2022 08:30AM
May 25, 2022 08:30AM
May 23, 2022 08:30AM
May 18, 2022 08:33AM
May 18, 2022 08:30AM
Mar 31, 2022 08:30AM Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
Mar 30, 2022 05:00PM
Jan 31, 2022 04:13PM
Jan 31, 2022 04:10PM
Jan 12, 2022 08:33AM
Jan 12, 2022 08:30AM
Jan 4, 2022 08:32AM
Jan 4, 2022 08:30AM Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs
Nov 16, 2021 08:30AM
Oct 6, 2021 08:32AM
Oct 6, 2021 08:30AM
Sep 28, 2021 08:30AM
May 17, 2021 05:15PM
Mar 31, 2021 04:45PM
Mar 2, 2021 08:15AM Tenax Therapeutics (TENX) Expands Board of Directors
Mar 2, 2021 08:15AM

322,898 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All